Speech-Language Pathologists in Oakland, MD Accepting Medicare

8 Speech-Language Pathologists found. Showing 1 - 8

Mrs. Amy Elizabeth Yoder-yutzy, MS, CCC, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 40 S 2nd St, Oakland, MD 21550 Phone: 301-914-1351    Fax: 301-334-7642

Tracie A Green, SLP,CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 40 S 2nd St, Oakland, MD 21550 Phone: 301-334-8900

Mrs. Pamela Firestone Trautwein, MS, CCC, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 40 S 2nd St, Oakland, MD 21550 Phone: 301-914-1351    Fax: 301-334-7642

Mrs. Katie Lynn Hogsett, MS, CCC, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 40 S 2nd St, Oakland, MD 21550 Phone: 301-914-1351    Fax: 301-334-7642

Western Maryland Speech And Swallowing Therapy Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 13141 Garrett Hwy, Oakland, MD 21550 Phone: 240-321-9191

Mrs. Michele Marie Snyder, MS, CCC, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 40 S 2nd St, Oakland, MD 21550 Phone: 301-914-1351    Fax: 301-334-7642

Dr. Beverly Jo Gallagher, PHD,CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 20294 Garrett Hwy Ste 1, Oakland, MD 21550 Phone: 310-387-5580    Fax: 443-927-9126

Norma J Heydon-wrather, MHS,CCC,SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6500 Thayer Ctr, Oakland, MD 21550 Phone: 301-334-1863

News Archive

DMC recommends ARIAD continue Phase 3 trial of oral ridaforolimus for metastatic sarcomas to final analysis

ARIAD Pharmaceuticals, Inc. today announced that the independent Data Monitoring Committee (DMC) of the Phase 3 SUCCEED trial has completed the second interim efficacy analysis as specified in the study protocol and has recommended that the randomized, placebo-controlled trial of oral ridaforolimus in patients with metastatic sarcomas continue to its final analysis, without modification to the study protocol.

SimQuest develops open-incision surgical simulation platform

SimQuest LLC, a leading developer of technology-assisted education and training, has developed the first platform for open-incision surgical simulation, which will enable surgeons to practice open surgical techniques with no risk to patients. The platform will allow surgeons to practice their skills in an environment that allows for errors and provide objective feedback on performance.

Covalon Technologies reports revenue of $1,002,394 for third fiscal quarter 2010

Covalon Technologies Ltd., an advanced medical technologies company, today announced the following financial results for its third fiscal quarter ended June 30, 2010

ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, provides an update on its development plans to broaden the scope of its lead product ERYASP into the large field of solid tumors and announces the launch of a Phase II study in pancreatic cancer.

OCD patients can benefit from exposure and response prevention therapy when drug treatment options fail

Patients with Obsessive-Compulsive Disorder (OCD) can improve their symptoms significantly by adding exposure and response prevention therapy to their treatment regimen when common drug treatment options have failed, according to new research from psychiatrists at the Perelman School of Medicine at the University of Pennsylvania.

Read more Medical News

› Verified 8 days ago